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บทคดัยอ่ 
วตัถปุระสงค:์ เพือ่ตรวจสอบผลของการใชท้รามาดอลร่วมกบัวาร์ฟารนิต่อระดบั
INR วิธีการศึกษา: การศกึษานี้เป็นแบบ prospective cohort ในผูป้่วยนอกของ
โรงพยาบาลกบนิทร์บุร ีจงัหวดัปราจนีบุรี ระหว่างเดอืนเมษายน - ตุลาคม พ.ศ. 
2558 มผีูป้่วยเขา้รว่มการวจิยัทัง้หมด 206 ราย ซึง่จ าแนกเป็น 2 กลุ่มไดแ้ก่ กลุ่ม
ทีไ่มไ่ดท้รามาดอลรว่มกบัวารฟ์ารนิ 103 ราย และกลุ่มทีไ่ดร้บัทรามาดอลร่วมกบั
วารฟ์ารนิ 103 ราย เก็บขอ้มูลผูป้่วยจากระบบคอมพวิเตอร์ของโรงพยาบาลและ
การสมัภาษณ์ ตดิตามการเปลีย่นแปลงระดบั INR ของผูป้่วยก่อนและหลงัเขา้ร่วม
การศกึษา มกีารวเิคราะห์ความแตกต่างระหว่างกลุ่มผูป้่วยดว้ยสถติ ิt-test และ 
chi-square test และแสดงผลค่าความเสีย่งสมัพทัธ์ (relative risk, RR) ผล
การศึกษา: เมือ่สิน้สุดการศกึษาพบวา่ ผูป้่วยในกลุม่ทีไ่ดร้บัวารฟ์ารนิร่วมกบัทรา
มาดอลม ีINR ออกนอกช่วงเป้าหมายมากกว่ากลุ่มทีก่ลุ่มทีไ่ดร้บัวาร์ฟารนิอย่าง
เดยีวอย่างมนีัยส าคญัทางสถติ ิ(47.57% vs. 26.21%; P < 0.001) โดยมคีวาม
เสีย่งของ INR ออกนอกช่วงเป้าหมายเป็น 1.61 เท่า (RR = 1.61, 95% CI = 
1.16 – 2.22) ไมพ่บการเกดิเหตุการณ์ไมพ่งึประสงคจ์ากการใชว้ารฟ์ารนิในผูป้่วย
ทัง้สองกลุ่ม สรปุ: การใช้ทรามาดอลร่วมกบัวาร์ฟารนิอาจท าใหร้ะดบั INR ออก
นอกช่วงการรกัษาได้ หากจ าเป็นต้องใช้ยานี้ร่วมกบัวาร์ฟารนิควรมกีารตดิตาม
ระดบั INR ของผูป้่วยอยา่งใกลช้ดิ  
ค าส าคญั: ทรามาดอล, วารฟ์ารนิ, ปฏกิริยิาระหวา่งยา, ไอเอน็อาร ์ 
 
Abstract 
Objective:  To examine the effects of tramadol concomitantly used with 
warfarin on the international normalized ratio (INR) levels. Method: This 
prospective cohort study was conducted in the outpatients who visited 
Kabinburi Hospital in Prachinburi Province from April to October 2015. Of 
206 patients, they were classified into two groups, i.e. 103 patients who did 
not receive tramadol with warfarin and 103 patients who received both 
drugs. Patients’ data were collected from the hospital’s online medical 
records and interviews. The INR levels of patients were monitored before 
and after they participated in the study. The differences between the two 
groups were analyzed using the t-test and chi-square test. Moreover, a 
relative risk (RR) was presented. Results: At the end of the study, patients 
receiving both drugs had the INRs out of the target range more than those 
receiving no tramadol (47.57% vs. 26.21%; P < 0.001). The patients 
receiving both drugs were 1.61 times more likely to experience the INRs 
out of the target (RR = 1.61; 95% CI: 1.16 – 2.22). No warfarin-associated 
adverse events were found in either group. Conclusion: The combination 
use of tramadol and warfarin could cause the out-of-target INR levels. If 
tramadol is needed, their INR levels should be closely monitored.  
Keywords: tramadol, warfarin, drug-drug interaction, INR 
Introduction 
It is widely known that oral anticoagulants are the 
primary drugs used in the treatment and prevention of 
thromboembolism, specifically for outpatients who are 
diagnosed with atrial fibrillation/flutter or venous thrombo-
embolism. One of the most common anticoagulants is 
warfarin, which can be effectively absorbed into the body.1 
However, it has a narrow therapeutic index and is therefore 
regarded as a high alert drug. The dosage of warfarin 
depends on the clinical results of each patient due to the 
variation in drug response. Nonetheless, it is possible to 
anticipate the dosage of warfarin given to each patient by 
monitoring the laboratory test results in accordance with the 
criteria stipulated by the World Health Organization. For 
instance, the international normalized ratio (INR), which is 
calculated by comparing the patient’s prothrombin time with 
the standard prothrombin time of a regular individual.2  
The expected outcome of warfarin is anticoagulation with 
the maintenance of the patient’s INR level to be in the 
therapeutic range. If the INR level of the patient falls under 
the therapeutic range, the patient will have an increased risk 
of thrombosis. On the other hand, if the INR level of the 
patient is higher than the therapeutic range, the patient will 
have a risk of hemorrhagic complication.3 In addition, drug-
drug interactions are regarded as an important factor that 
has a significant clinical effect on the action of warfarin, such 
as pharmacodynamic interactions and pharmacokinetic 
interactions in the process of absorption, distribution, or 
metabolism that cause changes in the level of warfarin.   
Tramadol is classified as a weak opioid and is used to 
relieve moderate to severe pain. Tramadol is metabolized by 
cytochromes P450 (CYP) that comprise of CYP2D6 and 
CYP3A4, as well as by conjugation reactions, N- and O-
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demethylation, glucuronidation, and sulfation.4 As for 
warfarin, it is metabolized by CYP2C9 (primary metabolism), 
CYP2C19, CYP2C8, CYP2C18, CYP1A2, and CYP3A4. 
According to the literature review, many case reports5-8 
found that tramadol caused a significant increase in the INR 
levels of patients, which is consistent with the nested case 
control study of Pottegård et al.9 In addition, the study also 
found that patients who received tramadol had a higher risk 
of an increase in INR level than those who did not receive 
tramadol by 3.1 times (odds ratio = 3.1, 95% CI = 1.9 - 5.2). 
Nonetheless, the study had some limitations in the aspect of 
other factors that could affect INR levels such as over 
consumption of green-leafy vegetables, consumption of 
nutritional supplements, and concomitant drug use. 
Moreover, concerning the fact that it was a retrospective 
study, there could be a selection bias. The mechanism 
pertaining to the reaction between tramadol and warfarin 
was not clearly known. Therefore in patients with CYP2D6 
polymorphism, metabolism of warfarin with the interaction 
with tramadol is even harder to predict.4,5,9  
To examine clinical outcomes as a result of the 
interaction between tramadol and warfarin in Thai patients, 
the researchers conducted a prospective cohort study in 
order to control various factors that could affect INR levels 
and to determine the reaction time between such two drugs 
by taking into consideration the changes in the level of INR 
before and after using tramadol. Specifically the research 
objective was to examine the relationship between the use of 
tramadol and the changes in the INR level of patients who 
were treated with warfarin. We hypothesized that patients 
who received tramadol in conjunction with warfarin will have 
INR levels outside the 2 - 3 range more than those who 
received warfarin with no tramadol.  
  
Methods 
  
This research was a prospective cohort study in order to 
control other factors that could affect INR levels and to 
determine the reaction time between the two aforementioned 
drugs by taking into consideration the changes in the level of 
INR before and after using tramadol. The study examined 
outpatients of Kabinburi Hospital in Prachinburi province who 
were treated with warfarin between April 21, 2015 and 
October 31, 2015. The selected patients had to be above 20 
years of age with the ability to read, write, and communicate. 
Moreover, the patients had to receive warfarin consecutively 
for at least 30 days. The INR levels of patients had to be 
within the 2 - 3 range after having been monitored for at 
least 3 times before participating in the study. Such criterion 
was necessary since it had been reported that tramadol can 
affect the action of warfarin on the first day of co-
administration.5-8 Likewise, such criterion also enabled the 
effects of tramadol on the changes of INR levels to be 
monitored more clearly. The INRs of the participating 
patients were prospectively taken at day 1 and day 7 of the 
study.  
The sample size was calculated using EpiTools software 
from AusVet Animal Health Services, with the confidence 
interval of 95% and the statistical power of 80%. The sample 
comprised of 206 patients, which was divided into 2 groups, 
the unexposed and exposed groups, of 103 patients each. 
The unexposed group consisted of patients who solely 
received warfarin, while the exposed group included patients 
who received warfarin concomitantly with tramadol.  
The data were collected from the medical records of 
patients on the first day of the study. The patients were 
monitored for another 7 days after which the patients would 
meet with their corresponding physicians in order to examine 
the level of INR. After that, the researcher would conduct an 
interview with the patients. Information collected through the 
interview included general information, history of the intake 
of food, food supplements, herbs or other medications, 
historical levels of INR, current medications, history of taking 
tramadol, compliance to the treatment, and other factors. 
Patients with factors that could potentially affect the INR 
were excluded. These factors included obvious herb 
consumptions, over consumption of green-leafy vegetables, 
consumption of nutritional supplements, and concomitant 
drug use. In addition, patients taking warfarin of less than 
80% of the prescribed dose based on pill count method were 
also excluded.  
The obtained data were analyzed using a software 
package, namely SPSS Version 16. The statistical 
significance was determined based on the P-value of 0.05. 
Moreover, descriptive statistics including frequency, 
percentage, mean, and standard deviation were used 
simultaneously with inferential statistics. The t-test for 
independent samples (two-sample t-test) was used in the 
event of normal distribution. Alternatively, if the data were 
not normally distributed, the Mann-Whitney U-test would be 
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used. In addition, differences in the variables were tested at 
a ratio scale between the two groups of patients. Meanwhile, 
chi-square test was used to determine the differences 
between countable variables or between categorical 
variables. The results were presented as a relative risk (RR) 
between the exposed group and the non-exposed group.  
This study was approved by the Ethic Committee of 
Naresuan University on April 20, 2015 (IRB No. 041/58).   
 
Results  
 
General information of participating patients  
Of 257 patients contacted for study participants, 10 were 
excluded because of loss of follow-up, while 4, 7, 9, 12, and 
9 patients were excluded because of the overconsumption of 
green-leafy vegetables, consumption of nutritional 
supplements, consumption of herb, concomitant drugs, and 
underuse of warfarin (less than 80% of prescribed  dose). As 
a result, a sample of 206 patients were achieved and 
analyzed accordingly. No adverse events associated with 
warfarin were found.  
Across the sample of 206 patients, there were roughly 
equal proportions of male (49.02%) and female (50.98%) 
patients (Table 1). Patients who received warfarin had the 
mean age of 67.5  14.2 years, while those receiving both 
warfarin and tramadol had the mean age of 68.4  12.6 
years. In the aspect of comorbidity, there were 77 patients 
(37.38%) with hypertension, 39 (18.93%) with hyperlipidemia, 
24 (11.65%) with diabetes mellitus, 11 (5.34%) with heart 
failure, and 59 (28.64%) with other diseases. The 
participating patients had been treated with warfarin for an 
average of 2.8  2.1 years. In addition, indications for 
warfarin consisted of atrial fibrillation, heart valve disease, 
deep vein thrombosis, pulmonary embolism, and other 
conditions, which accounted for 119 (59.21%), 29 (14.08%), 
22 (10.68%), 15 (7.28%), and 25 (12.14%) patients, 
respectively (Table 1).  
 
Average INR levels  
This research monitored the INR level of each patient for 
a total of 4 times. Upon the completion of the research, the 
unexposed group had the average INR level of 2.60  0.45 
which was lower than that in the exposed group (3.10   
0.83), with a statistical significance (P-value < 0.001) (Table 
2).  
 
 
 Table 1  General characteristics of the patients (N = 206).  
Characteristics 
N (%) by groups 
P-value Unexposed Group  
(N = 103) 
Exposed Group  
(N = 103) 
Gender*   0.6777 
- Male 52 (50.49) 49 (47.57)  
- Female 51 (49.51) 54 (52.43)  
Age (year)#  67.5 ± 14.2 68.4 ± 12.6 0.6264 
History of allergies*   0.2435 
- Yes  8 (7.77) 12 (11.65)  
- No  95 (02.23) 91 (88.35)  
Chronic diseases*    
- Hypertension 36 (33.64) 41 (39.81) 0.2020 
- Hyperlipidemia 18 (16.82) 21 (20.39) 0.4365 
- Diabetes Mellitus 10 (9.35) 14 (13.59) 0.3124 
- Heart failure 8 (7.48) 3 (2.91) 0.2698 
- Others 35 (32.71) 24 (23.30) 0.0912 
Average number of years of 
warfarin use# 
2.7 ± 1.9 2.9 ± 2.3 0.4693 
Warfarin indications*    
- Atrial fibrillation 58 (54.72) 61 (58.65) 0.3424 
- Heart valve disease 18 (16.98) 11 (10.58) 0.2260 
- Deep vein thrombosis 13 (12.26) 9 (8.65) 0.2978 
- Pulmonary embolism 7 (6.60) 8 (7.70) 0.6514 
- Others 10 (9.43) 15 (14.42) 0.1421 
   * chi-square test for categorical data for statistical analysis  
   # two-sample t-test continuous data for statistical analysis  
 
 Table 2  Changes in the INR levels (N = 206).  
Time of INR monitoring 
Average level of INR 
P-Value* 
Unexposed 
group  
(N = 103) 
Exposed 
group  
(N = 103) 
Historical value (1st time) 2.51 ± 0.32 2.54 ± 0.36 0.10 
Historical value (2nd time) 2.43 ± 0.30 2.42 ± 0.31 0.79 
Prior to the study (Day 1) 2.50 ± 0.42 2.50 ± 0.48 0.74 
After the study (Day 7) 2.60 ± 0.45 3.10 ± 0.83 < 0.001 
* Two-sample t-test was used in the statistical analysis  
 
 
INR out of target range  
At the end of the study, 49 of 103 patients in the 
exposed group had their INR out of the target range 
(47.57%). As expected, only 27 of 103 patients in the 
unexposed group (26.21%) experienced an out-of-range 
INR. This difference was found statistically significant (P-
value = 0.002). In terms of relative risk, patients using 
warfarin and tramadol was 1.61 times more likely to have the 
INR out of target compared with those receiving warfarin 
only (RR = 1.61, 95% CI = 1.16 – 2.22).  
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 Table 3  Relative risk of out-of-range INR among patients 
receiving warfarin plus compared with those receiving warfarin 
(N = 206).  
Groups  
INR out of 2 – 3 range, N (%) 
Yes No 
Exposed group 49 (47.57%) 54 (52.43%) 
Unexposed group 27 (26.21%) 76 (73.79%) 
RR = 1.61, 95% CI = 1.16 – 2.22, P-value = 0.002.  
 
Tramadol doses that may cause INR level out of the 2 – 3 
range  
It was found that the average dose of tramadol among 
patients that had INR level outside the 2 - 3 range was 
355.0  20.0 mg/week. On the contrary, among those 
patients with INR within the 2 – 3 range, their average dose 
of warfarin was 205.0  11.5 mg/week. The difference 
between the aforementioned doses of tramadol was 
statistically significant (P-value < 0.001).  
 
 
Discussions and Conclusion  
 
Our study found that the use of tramadol in conjunction 
with warfarin caused the level of INR to be out of range. 
Patients who received warfarin with tramadol had 1.61 times 
higher chance of having out-of-range INR levels than 
patients who did not take tramadol (RR = 1.61, 95% CI = 
1.16 – 2.22). Such difference was statistically significant at a 
P-value of 0.002. Our finding was in accordance with the 
research conducted by Anton Pottegård et al. in 2014.10 
They conducted a descriptive research in 513 patients who 
were able to control their INR levels. The results indicated 
that the use of tramadol concomitantly with tramadol caused 
the level of INR to increase by more than 4 times and up to 
1.80 incidents per person per year at the 95% confidence 
interval of 1.53 – 2.10.  
Since the interaction between tramadol and warfarin has 
not yet been clearly identified, the recommendation to 
manage the administrations of the two drugs has not been 
issued. Therefore we recommended the weekly dose of 
tramadol to be no more than 350 milligrams in the event that 
it is necessary for patients to receive tramadol concomitantly 
with warfarin. We also suggest that it is significant to closely 
observe the side effects of warfarin. In case of abnormal 
symptoms, the patients should visit the doctor immediately.  
The limitations of this research encompassed the fact 
that patients also received concomitant medications other 
than tramadol. This could confound the results. Moreover, 
concerning the lack of clarity on the reaction between 
tramadol and warfarin, it was uncertain whether tramadol 
actually caused the changes in the INR level of patients who 
were treated with warfarin. Accordingly, it is significant to 
study the mechanism pertaining to the reaction between 
tramadol and warfarin in future researches.  
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